-
Electronic (PDF)
-
Site License
-
Enterprisewide
Dyax Corp.: Company Profile and SWOT Analysis
iCD Research, December 2011, Pages: 40
Synopsis
ICD Research's "Dyax Corp.: Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, SWOT analysis, key facts, information on products and services plus information on key news events affecting the company.
Summary
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
ICD Research's "Dyax Corp.: Company Profile and SWOT Analysis" report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. ICD Research strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Scope
- Examines and identifies key information and issues about "Dyax Corp." for business intelligence requirements
- Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
- Provides analysis on financial ratios of the company along with a competitor benchmarking section
- The profile also contains information on business operations, company history, major products and services, prospects, key competitors, key employees
Reasons To Buy
- Quickly enhance your understanding of the company
- Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
- Increase business/sales activities by understanding your competitors’ businesses better
- Recognize potential partnerships and suppliers
- Obtain yearly profitability figures
Key Highlights
Dyax Corp. (Dyax) is a biopharmaceutical company that specializes in the discovery, development, and commercialization of novel biotherapeutics for inflammatory, oncology and other indications. The company's lead product candidate, DX-88 received approval from the US FDA (United States Food and Drug Administration) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. It markets its DX-88 under the brand name, KALBITOR (ecallantide) in the US. In addition, the company develops DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for the treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), a part of sanofi-aventis. Furthermore, Dyax identifies new drug candidates using phage display technology. Its other drug candidates include DX-2240 and DX-2400. Dyax is headquartered in Cambridge, Massachusetts, the US.
1 Business Analysis
1.1 Company Overview
1.2 Business Description
1.3 Major Products and Services
2 Analysis of Key Performance Indicators
2.1 Five Year Snapshot: Overview of Financial and Operational Performance Indicators
2.2 Key Financial Performance Indicators
2.2.1 Revenue and Operating Profit
2.2.2 Asset, Liabilities and Capex
2.2.3 Net Debt vs. Gearing Ratio
2.2.4 Operational Efficiency
2.2.5 Solvency
2.3 competitive benchmarking
2.3.1 Efficiency
2.3.2 Capital Expenditure
2.3.3 Turnover - Inventory and Asset
3 Mergers & Acquisitions and Partnerships
3.1 M&A and Partnerships Strategy
4 Recent Developments
5 SWOT Analysis
5.1 SWOT Analysis - Overview
5.2 Strengths
5.3 Weaknesses
5.4 Opportunities
5.5 Threats
6 Dyax Corp. - Company Statement
7 history
8 Dyax Corp. - Key employees
9 Key employee Biographies
10 Appendix
10.1 Methodology
10.2 Ratio Definitions
10.3 Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
